Epigenetic inactivation of the thyroid hormone receptor β1 gene at 3p24.2 in lung cancer

Annals of Surgical Oncology

Volumn 17, Issue 8, 2010, Pages 2222-2228

  Iwasaki, Yasuki ^a   Sunaga, Noriaki ^a   Tomizawa, Yoshio ^b   Imai, Hisao ^a   Iijima, Hironobu ^b   Yanagitani, Noriko ^a   Horiguchi, Kazuhiko ^a   Yamada, Masanobu ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; THYROID HORMONE RECEPTOR BETA; THYROID HORMONE RECEPTOR BETA 1; TRICHOSTATIN A; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; CHROMOSOME 3P; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA METHYLATION; CHROMOSOME 3; GENETIC EPIGENESIS; GENETICS; HETEROZYGOSITY LOSS; LUNG TUMOR; METABOLISM; METHYLATION; NON SMALL CELL LUNG CANCER; SMALL CELL LUNG CANCER; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 3; EPIGENESIS, GENETIC; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; METHYLATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMALL CELL LUNG CARCINOMA; THYROID HORMONE RECEPTORS BETA;

EID: 77954948707     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-0956-9     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell. 2002;1:49-52.
3. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007;2:327-43.
4. Hung J, Kishimoto Y, Sugio K et al. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA. 1995;273:558-63.
5. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163-7.
6. Zochbauer-Muller S, Minna JD, Gazdar AF. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist. 2002;7:451-7.
7. Tomizawa Y, Iijima H, Nomoto T, et al. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with nonsmall cell lung cancer. Lung Cancer. 2004;46:305-12.
8. Laudet V, Begue A, Henry-Duthoit C, et al. Genomic organization of the human thyroid hormone receptor alpha (c-erbA-1) gene. Nucleic Acids Res. 1991;19:1105-12.
9. Escriva H, Delaunay F, Laudet V. Ligand binding and nuclear receptor evolution. Bioessays. 2000;22:717-27.
10. Cheng SY. Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev Endocr Metab Disord. 2000;1:9-18.
11. Li Z, Meng ZH, Chandrasekaran R, et al. Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. Cancer Res. 2002;62:1939-43.
12. Silva JM, Dominguez G, Gonzalez-Sancho JM, et al. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene. 2002;21:4307-16.
13. Lin KH, Shieh HY, Chen SL, Hsu HC. Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog. 1999;26:53-61.
14. Puzianowska-Kuznicka M, Krystyniak A, Madej A, et al. Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab. 2002;87:1120-8.
15. Joseph B, Ji M, Liu D, et al. Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors. J Clin Endocrinol Metab. 2007;92:4766-70.
16. Ando S, Sarlis NJ, Oldfield EH, Yen PM. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab. 2001;86:5572-6.
17. Kamiya Y, Puzianowska-Kuznicka M, McPhie P, et al. Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis. 2002;23:25-33.
18. Dunwell TL, Hesson LB, Pavlova T, et al. Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics. 2009;4:185-93.
19. Dobrovic A, Houle B, Belouchi A, Bradley WE. erbA-related sequence coding for DNA-binding hormone receptor localized to chromosome 3p21-3p25 and deleted in small cell lung carcinoma. Cancer Res. 1988;48:682-5.
20. Garcia-Silva S, Aranda A. The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation, and transformation. Mol Cell Biol. 2004;24:7514-23.
21. Martinez-Iglesias O, Garcia-Silva S, Tenbaum SP, et al. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res. 2009;69:501-9.
22. Yokota J, Wada M, Shimosato Y, et al. Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 1987;84:9252-6.
23. Sunaga N, Miyajima K, Suzuki M, et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res. 2004;64:4277-85.
24. Iijima H, Tomizawa Y, Iwasaki Y, et al. Genetic and epigenetic inactivation of LTF gene at 3p21.3 in lung cancers. Int J Cancer. 2006;118:797-801.
25. Tomizawa Y, Iijima H, Sunaga N, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res. 2005;11:6816-22. (Pubitemid 41428736)
26. Bogos K, Renyi-Vamos F, Kovacs G, et al. Role of retinoic receptors in lung carcinogenesis. J Exp Clin Cancer Res. 2008;27:18.
27. Virmani AK, Rathi A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst. 2000;92:1303-7.
28. Gazdar AF, Minna JD. Multifocal lung cancers-clonality vs field cancerization and does it matter? J Natl Cancer Inst. 2009;101:541-3.
29. Morita S, Okamoto I, Kobayashi K, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2009;15:4493-8.
30. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007;13:2890-6.
31. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2: e17.